CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

CJC-1295 Peptide (No DAC)

CJC-1295 is a synthetic peptide derivative of the naturally occurring GHRH hormones and is composed of 29 amino acids.⁽²⁾ This peptide is also referred to as DAC GRF (i.e., Drug Affinity Complex Growth hormone Releasing Factor). CJC-1295 NO DAC, also sometimes called Modified GRF (1-29) or CJC 1295 without DAC, is a modified version of the peptide containing four substituted amino groups that are considered to help prevent the peptide's degradation.

Modified growth hormone fragments GRF (1-29) were first discovered in the early 1980s where it was suggested that the first 29 amino acids of the natural growth hormone releasing hormone might retain all the properties of the full 44 amino acid peptide.⁽³⁾ One of the potential drawbacks of synthetically developed growth hormone releasing peptides is a short half-life. Rigorous research has resulted in a supposedly stabilized, longer lasting CJC-1295 (No DAC) peptide.⁽⁴⁾

Overview

CJC-1295 NO DAC peptide appears to augment the production of the growth hormone by binding to the serum albumin via a free thiol group and forming a covalent disulfide bond.⁽⁵⁾ This potential action may trigger a small part of the pituitary gland which then releases higher concentrations of naturally occurring growth hormone, thereby potentially helping to maintain an equilibrium.

Given that this peptide also possesses four amino acid substitutions in its structure, it may exhibit enhanced bioactivity and resistance towards the proteolytic enzymes. The peptide may bind covalently to albumin but may also have trace amounts bound to fibrinogen and immunoglobulin G (IgG).⁽⁴⁾ This event could possibly lead to elevated levels of plasma growth hormone as well as insulin-like growth factor 1, or IGF-1.

Chemical Makeup

Molecular formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular weight: 3367.9 g/mol
Other known titles: CJC-1295 Without DAC
 

Research and Clinical Studies

Growth Hormone Secretagogues (GHSs) and Growth Hormone Releasing Hormones (GHRHs)

In one study,⁽⁶⁾ researchers attempted to define the potential of growth hormone secretagogues (GHSs) and growth hormone releasing hormones (GHRHs) – the class of hormones to which CJC-1295 no DAC peptide is considered by scientists to belong to. Several analogues were given to the test subjects, who were then monitored for any physiological changes. As an outcome of this long lasting study, it was theorized by the researchers that these hormones may lead to improved growth velocity, stimulate appetite, and improve lean mass.

CJC-1295 (No DAC) Peptide and Growth Hormone Pulsatility

In the early 2000s,⁽⁷⁾ a clinical trial was conducted on male test subjects aged between 20 and 40 years of age. The subjects were divided into two groups - one was given a placebo and the other group was given the peptide. Blood was sampled out from the subjects one week before and after the presence of CJC-1295 peptide (or placebo) to monitor the levels of growth hormone pulsatility. At the end of the study, it was suggested by the researchers that CJC-1295 appeared to have led a 7.5-fold increase in the growth hormone pulsatility levels as compared to that of the placebo. These levels reportedly increased gradually through the study and remained unaltered even after one week following the trial period.

In another study, subjects aged between 21 and 61 years were examined in two double-blind trials⁽⁸⁾ over a period of 28 days. Subjects were divided into two groups; one group received a placebo, the other received the peptide. At the end of the first round, it was suggested by the researchers that there appeared to be a dependent increment in the mean plasma growth hormone level by up to 10 folds for more than 6 days and in the levels of IGF-1 concentrations by up to 3 folds for up to 11 days. In the second round, it was suggested that with multiple instances of peptide presence, the mean levels of the growth hormone and IGF-1 appeared to remain above baseline for up to 28 days.

CJC-1295 (No DAC) Peptide and Intestinal Studies

Studies⁽⁹⁾ were conducted in monkeys which have suggested an interaction between GHRH analog peptides and VPAC(1)-R, found on the smooth muscles of the gastrointestinal system. This interaction was suggested to induce bowel movement, though the potential connection between specific peptides and bowel release are still under investigation.

CJC-1295 (No DAC) Peptide and Heart Rate

Preliminary research⁽¹⁰⁾ in rodents suggested that Modified GRF 1-29 peptide (along with other GHRH derivative analogs) may exhibit some potential to improve heart rate, and possibly support the heart's ability to pump blood, particularly following a heart attack. These NIH studies⁽¹⁰⁾ reported that GHRH agonist peptides appeared to promote cardiac tissue repair and possibly also improve ejection fraction rates.

CJC-1295 (No DAC) Peptide and Thyroid, Growth Hormones

Researchers conducted a study⁽¹¹⁾ in subjects with primary hypothyroidism before and after thyroid replacement operations. 14 subjects between the ages of 26 and 60 were presented with Modified GRF peptides before and after replacement. Following the study, the levels of growth hormones were monitored. Results suggested that the test subjects appeared to respond more to GRF peptide after thyroid replacement than before.

CJC-1295 (No DAC) Peptide and Combination

CJC-1295 NO DAC appears to be a longer lasting GHRH analogue compared to other synthetic GHRH (and GHS) peptides. Consequently, when combined with other short acting peptides, it may support longer duration for specific properties. One such highly common peptide combination is with Ipamorelin, a synthetic GHRH pentapeptide. Both Ipamorelin and CJC peptides have been suggested to host similar modes of action, particularly acting upon the anterior pituitary gland and possibly stimulating growth hormone secretion.

CJC-1295 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.

References:

1. A Giustina, JD Veldhius, Pathophysiology of the neuro regulation of growth hormone secretion in experimental animals and the human, Endocrinology, 1 December 1998, https://europepmc.org/article/med/9861545
2. National Center for Biotechnology Information. "PubChem Compound Summary for CID 91976842, CJC1295 Without DAC" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC
3. Clark, R G, and I C Robinson. “Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats.” Nature vol. 314,6008 (1985): 281-3. https://pubmed.ncbi.nlm.nih.gov/2858818/
4. The Discovery of Growth Hormone-Releasing Hormone: An Update https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2826.2008.01740.x
5. Sackmann-Sala, Lucila et al. “Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.” Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society vol. 19,6 (2009): 471-7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787983/
6. Sigalos, John T, and Alexander W Pastuszak. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews vol. 6,1 (2018): 45-53. doi:10.1016/j.sxmr.2017.02.004 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632578/
7. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
8. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
9. Ito T, Igarashi H, Pradhan TK, Hou W, Mantey SA, Taylor JE, Murphy WA, Coy DH, Jensen RT. GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity. Peptides. 2001 Jul;22(7):1139-51. https://pubmed.ncbi.nlm.nih.gov/11445245/
10. Schally AV, Zhang X, Cai R, Hare JM, Granata R, Bartoli M. Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists. Endocrinology. 2019 Jul 1;160(7):1600-1612. https://pubmed.ncbi.nlm.nih.gov/31070727/
11. Valcavi R, Jordan V, Dieguez C, John R, Manicardi E, Portioli I, Rodriguez-Arnao MD, Gomez-Pan A, Hall R, Scanlon MF. Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine. Clin Endocrinol (Oxf). 1986 Jun;24(6):693-8. https://pubmed.ncbi.nlm.nih.gov/3098458/
12. Gobburu JV, Agersø H, Jusko WJ, Ynddal L (September 1999). "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers". Pharmaceutical Research. 16 (9): 1412–6. doi:10.1023/A:1018955126402 https://en.wikipedia.org/wiki/Ipamorelin#cite_note-GobburuAgers%C3%B81999-1